{"id":"W2142170680","doi":"10.1634/theoncologist.2011-0237","title":"Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Angiosarcoma; Medicine; Sorafenib; Sarcoma; Soft tissue sarcoma; Clinical endpoint; Internal medicine; Surgery; Toxicity; Oncology; Chemotherapy; Clinical trial; Pathology; Hepatocellular carcinoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005646895,0.0002807323,0.000480765,0.00003164792,0.0005967571,0.00002943094,0.0003702299,0.0001036668,0.0001041344],"category_scores_gemma":[0.0002763613,0.000126265,0.0003313889,0.0002059522,0.0003290772,0.0001376975,0.0001408782,0.0002678619,0.00002553957],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001075145,"about_ca_system_score_gemma":0.00008473209,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002281022,"about_ca_topic_score_gemma":0.000122495,"domain_scores_codex":[0.9982258,0.0001510037,0.0003353398,0.0002927571,0.0003884421,0.0006066605],"domain_scores_gemma":[0.9982448,0.0005301278,0.0002118813,0.0007377879,0.0001030464,0.0001723785],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2176005,0.06934869,0.1556215,0.0001521643,0.002856519,0.000120347,0.009987747,0.00001219374,0.003745353,0.005735107,0.1329541,0.4018658],"study_design_scores_gemma":[0.4133177,0.03521223,0.1940479,0.0001723591,0.00165926,0.0000353569,0.0008777402,0.0001325848,0.0004458637,0.001064588,0.3523201,0.0007143124],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900924,0.001555065,0.0006054003,0.003231157,0.000597955,0.003059003,0.0001369747,0.00009354351,0.0006284835],"genre_scores_gemma":[0.9938969,0.00001782519,0.002273283,0.001146978,0.001470869,0.0003948352,0.0003605752,0.00004538592,0.0003933415],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4011515,"threshold_uncertainty_score":0.5148938,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02287312741647877,"score_gpt":0.2980100239155186,"score_spread":0.2751368964990398,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}